MDM2 and prostate carcinoma: The oncoprints of prostate adenocarcinoma (from the TCGA PanCancer study) and metastatic castration-resistant prostate cancer from the study by Abida et al. show the distribution of amplification of the IL-6 receptor (IL-6R), STAT3, and MDM2 genes in prostate tumors that carry unaltered and altered TP53 (Fig. 6a)41,42.